Citations

Showing 10 of 108152 citations.

Abstract 1756: Determination of the Mechanism of Elevated Left Ventricular Filling Pressures with Exercise: A Simultaneous Echocardiographic-Catheterization Study
Jaber, Wissam , Redfield, Margaret M. , Lee, Pui W, Ommen, Steve R. , Sorajja, Paul , Borlaug, Barry A. , Sorajja, Paul , Lam, Carolyn S.P. , Nishimura, Rick A.

Mayo Clinic

Circulation | July 3, 2021 | Volume: 116 | Issue: suppl_16 | Pages: No page available

10.1161/circ.116.suppl_16.ii_371-a Get It

Background: Exercise normally enhances LV relaxation with minimal change in filling pressure (P). We hypothesize that exercise in hypertensive (HTN) patients increases LV diastolic P through a direct effect on relaxation and ventricular-vascular coupling. Methods: Patients (n=21) with HTN, normal EF, and no coronary disease underwent simultaneous micromanometer LV P and echo-Doppler measurements at rest and with low level supine exercise (12 bicycle; 9 arm weight). Continuous volume (V) was obtained from mitral Doppler inflow and end-diastolic (ED) and end-systolic (ES) V from 2-D echo. Relaxation-corrected LV diastolic P was used for PV relationship P = α.e β*V ; to account for covariance in α and β, LV capacitance (EDV 20 = Ln[20mmHg/α]/β) was reported. Single beat method was used for LV ES elastance (Ees). Group 1 did not increase mean LV diastolic P (mDP) with exercise, Group 2 increased mDP >6mmHg. Results: LV diastolic P and arterial and LV ES elastance increased with exercise; EDV was stable; EDV 20 decreased. Compared to Group 1, Group 2 had a greater exercise-induced increase in afterload, associated with increase in LV minimal P and impaired augmentation of relaxation rate (Table & Figure ). Conclusions: In patients with HTN, impairment of ventricular relaxation plays a major role in causing LV filling P increase with exercise, which is related to ventricular-vascular coupling.
Abstract 1743: Identification of a Novel Susceptibility Locus at 9q21 for Familial Bicuspid Aortic Valve Disease
Yagubyan, Marineh, Majumdar, Ramanath, Tester, David J. , Ackerman, Michael J. , Sundt, Thoralf M. , McKellar, Stephen H. , Andrade, Mariza de , Garg, Vidu

Mayo Clinic

Circulation | July 3, 2021 | Volume: 116 | Issue: suppl_16 | Pages: No page available

10.1161/circ.116.suppl_16.ii_368 Get It

Background: Bicuspid aortic valve disease (BAV), the most common congenital cardiovascular malformation, has an incidence of 0.5–1.0% of live births. While most cases of BAV appear to be sporadic, familial inheritance patterns have been observed consistent with autosomal dominant inheritance with variable penetrance. However, little is known about specific genetic loci responsible for familial BAV. Here, we performed linkage analysis on a large multi-generational pedigree affected with BAV. Methods: We identified a large, five-generation pedigree (136 family members) with 10 individuals having BAV. Two-dimensional echocardiography was used to assign aortic valve phenotype. Genome-wide linkage analysis using 430 microsatellite markers (Marshfield Clinic) and fine mapping using 100 single nucleotide polymorphisms (Affymetrix) on chromosome 9 was performed on genomic DNA from all available family members. Logarithm of odds (LOD) scores of >2.0 were considered suggestive of linkage. Comprehensive splice site/open reading frame mutational analysis of candidate genes residing in the putative locus is underway using PCR, DHPLC, and DNA sequencing. A candidate gene, KLF9, Krüppel-like factor 9 was analyzed for mutations because of its role in cardiogenesis. Results: Multi-point genome-wide linkage analysis demonstrated a 7 cM region on chromosome 9q21 that was suggestive of linkage for familial BAV with a maximum multipoint LOD score of 2.8 flanked by the microsatellite markers GATA7D12 and D9S1834. This region contains several candidate genes with biological plausibility for BAV phenotype. KLF9- encoded Krüppel-like factor 9, localized to chromosome 9q21, was targeted as a prime candidate gene for familial BAV. However, no mutations involving the translated exons of KLF9 were detected. Further fine mapping studies and candidate gene analysis are currently underway. Conclusions: We report a novel susceptibility locus on chromosome 9q21 for BAV in a large multi-generational family. Although coding region mutations in KLF9 are not responsible for BAV in this pedigree, several candidate genes with biological plausibility for the development of congenital BAV lie within this region and warrant further scrutiny.
Abstract 1733: Complete Ablation of Typical Atrial Flutter in Patients with Corrected Congenital Heart Defects: “Non-Traditional” Access to the Surgically Excluded Cavotricuspid Isthmus
Yaman, Malek M. El, Packer, Douglas L. , Porter, Co-burn J., Asirvatham, Samuel J.

Mayo Clinic

Circulation | July 3, 2021 | Volume: 116 | Issue: suppl_16 | Pages: No page available

10.1161/circ.116.suppl_16.ii_365-b Get It

Background: Although multiple macroreentrant atrial flutters are seen in postoperative patients with congenital heart disease, cavotricuspid isthmus (CVTI) dependent flutter remains a fairly common arrhythmia in this group. When a Fontan or atrial switch (Mustard/Senning) type of procedure is performed, a portion of the CVTI is excluded from catheter access obtainable via a systemic venous route. We evaluated different techniques to access this excluded portion and completely ablate CVTI dependent flutter. Methods/Results: Between 1990 and 2007, 140 patients with surgically corrected congenital heart disease underwent an ablation procedure at our institution. Their records were reviewed to identify those with prior Fontan or atrial switch procedure who had documented CVTI dependent flutter requiring ablation. Data collected included methods of catheter access, circuits observed or induced, the location and number of ablation lines, immediate and long-term success, and complications. Results: Sixteen patients were identified (14, Fontan; 2, Mustard). In 12/16 (75%) patients bidirectional block of CVTI dependent flutter could not be achieved by right atrial (venous approach) ablation alone. In 7 of those, the excluded portion of the CVTI was targeted for ablation. This was accomplished by a retrograde transaortic approach via an interventricular communication then through the right atrioventricular valve (5 patients). Another retrograde transaortic approach was used with the catheter crossing the left atrioventricular valve then an atrial septal communication (one patient). A third approach involved an antegrade transconduit puncture (one patient). In all 7 patients, successful ablation of CVTI dependent flutter with bidirectional block was achieved. Post-procedure, one patient had temporary AV block requiring pacemaker placement. Follow-up was available on 4/7 patients (3 to 22 months, mean 10 months) with no documented recurrence of their CVTI dependent flutter. Conclusion: Even when surgical procedures exclude a portion of the CVTI, complete ablation for typical atrial flutter with resulting bidirectional block can be achieved via “non-traditional” approaches targeting the surgically excluded arrhythmogenic tissue.
Abstract 1664: Impact of Ischemic Burden and Revascularization on Outcomes among Patients Receiving Drug Therapy Versus an Implantable Cardioverter Defibrillator in MUSTT: Evidence for Ischemia Induced Proarrhythmia
Crandall, Mark A., Bunch, T. Jared , Munger, Thomas M. , Hafley, Gail E., Lee, Kerry L. , Buxton, Alfred E. , Packer, Douglas L.

Mayo Clinic

Circulation | July 3, 2021 | Volume: 116 | Issue: suppl_16 | Pages: No page available

10.1161/circ.116.suppl_16.ii_349 Get It

Background. ICD implantation for primary prevention of sudden death in patients with ischemic cardiomyopathy and left ventricular dysfunction is well established. However debate exists between the relationship between ischemia and the proarrhythmic state. Persistent ischemia may counter antiarrhythmic (AA) drug and/or device efficacy. Furthermore, the extent to which revascularization mitigates this influence of ischemia on efficacy is unknown. Methods . 704 patients enrolled in the MUSTT trial were studied. Ischemia was determined by the presence of angina within 6 weeks of enrollment and ≥ 2 reversible thallium defects. Revascularization was characterized as CABG or PTCA within 1 year of enrollment or the use of thrombolytics with the sentinal myocardial infarction (MI). We compared groups who were randomized to background medical treatment (BG Rx) verses those who were randomized to AA drug therapy in addition to EP testing (EP AARx). Results . 507 (81%) patients had ≤2 vessel CAD, whereas the remaining 19% had 3 vessel disease. 268 patients reported angina within 6 weeks of study enrollment. Thallium imaging revealed 0–1 defects in 458 (65%) and ≥2 in another 246 (35%). Those with ≥ 2 defects on Thallium and angina within 6 weeks of device implant had a significantly lower 5-year freedom from mortality in the EP AARx and BG Rx cohorts (Table ). Patients with EP AARx had an 8% lower mortality than those with BG Rx therapy alone if they received thrombolytics. However, if they did not receive thrombolytics, their mortality rate was 5% higher than the BG Rx group. Conclusion . Outcomes are worse in patients on antiarrhythmic therapy with ischemic factors compared to those on background therapy alone, particularly in the setting of recent angina. A proarrhythmic effect from antiarrhythmic drug therapy in patients with ischemia may underlie the higher mortality. ICD therapy mitigates the negative long-term effect of ischemia on mortality in those treated with AA therapy. Five Year Freedom from Mortality
Abstract 1606: High Specificity of Prolonged Isovolumic Contraction Time for Reverse Remodeling Associated with Cardiac Resynchronization Therapy
Miyazaki, Chinami , Redfield, Margaret M. , Espinosa, Raúl E. , Hayes, David L. , Oh, Jae K. , Bruce, Charles J.

Mayo Clinic

Circulation | July 3, 2021 | Volume: 116 | Issue: suppl_16 | Pages: No page available

10.1161/circ.116.suppl_16.ii_335-d Get It

Background: Isovolumic contraction time (ICT) and pre-ejection period (PEP) are altered by electrical conduction delay as well as impaired contractility. An abnormal PEP has been used to select patients for cardiac resynchronization therapy (CRT), however, the predictive value of PEP for reverse remodeling (RR) has not been reported. The purpose of this study is to determine the predictive value of ICT and PEP for the RR in a prospective, single center CRT registry. Methods: Prospective registry of all heart failure patients undergoing CRT with echo pre-implant and at 3 and 6 months after implant. PEP was measured from the ECG Q wave onset to the aortic valve opening from the left ventricular outflow tract pulsed-wave Doppler tracing. The timing interval from the QRS onset to mitral valve closure was measured (mitral valve closure time). ICT was calculated as PEP-mitral valve closure time. RR was defined as >15% reduction in end-systolic volume (ESV) measured by biplane Simpson’s method. Death due to cardiac cause and heart transplantation during the 6 month period were considered as a non-response in the receiver-operating characteristics (ROC)analysis. Results: Echocardiography data was available in 83 patients at 3 and 59 patients at 6 month after CRT. RR occurred in 42 patients (51%) at 3 months and in 32 (54%) patients at 6 months By ROC analysis, the area under the curve (AUC) for predicting RR was 0.74 for ICT (p<0.001) and 0.73 for PEP (p=0.001) (See table ). ICT>123 ms yielded a very high specificity of 90–93% to predict responders at 6 month after CRT either in entire population or after excluding the patients with atrial fibrillation. Conclusion: A prolonged ICT is highly specific for predicting reverse remodeling after CRT although it is found in a limited number of patients. A strategy employing a screening ICT measurement may identify patients highly likely to achieve reverse remodeling after CRT, but can not be used to exclude patients for CRT. ROC analysis
Abstract 1602: Strain-derived and Tissue velocity-derived Dyssynchrony Indexes for Prediction of Reverse Remodeling with Cardiac Resynchronization Therapy
Miyazaki, Chinami , Redfield, Margaret M. , Espinosa, Raúl E. , Hayes, David L. , Miller, Fletcher A., Oh, Jae K. , Bruce, Charles J.

Mayo Clinic

Circulation | July 3, 2021 | Volume: 116 | Issue: suppl_16 | Pages: No page available

10.1161/circ.116.suppl_16.ii_335 Get It

Background : Dyssynchrony indexes derived from time to peak systolic velocity and time to peak strain have been reported to predict left ventricular reverse remodeling (RR) after cardiac resynchronization therapy (CRT). The predictive characteristics of these indices have not been validated in a variety of clinical settings. Our objective was to determine the predictive value of strain and tissue velocity derived dyssynchrony indices for RR or clinical response to CRT in a prospective single-center CRT registry. Methods : Prospective registry of all heart failure patients (pts) undergoing CRT with echo before and 3 and 6 months after CRT. Color -coded tissue Doppler imaging in 12 segments was used to calculate the standard deviation of time to peak strain (Tϵ-SD) and time to peak systolic velocity (Tv-SD). RR was defined as a decrease in end systolic volume (ESV; biplane Simpson’s method) ≥15%. Indices were assessed with receiver-operating characteristics (ROC) analysis and the area under the curve (AUC) calculated in all pts and excluding those with atrial fibrillation at implant. Results : To date, of the first 87 patients, 4 died (classified as non-responder); 83 pts had 3 and 59 pts had 6 month echocardiography follow-up. Tϵ-SD (93%) and Tv-SD (98%) were feasible in most pts. RR occurred in 42 pts (51%) at 3 month and 32 patients (54%) at 6 month follow-up. See table . Tϵ-SD was superior to Tv-SD for prediction of RR in all pts and in those without atrial fibrillation. Findings were similar regardless of ischemic (68% of patients) or non-ischemic etiology. Neither baseline Tϵ-SD nor Tv-SD correlated with the improvement in clinical response measured by the change in six minute walk distance or peak VO 2 at 3 or 6 month after CRT (data not shown). Conclusions : In this single center experience, mechanical dyssynchrony measured by strain imaging but not tissue velocity imaging was predictive of RR. Neither index predicted clinical response.
Abstract 1589: Pulmonary Hypertension Is Associated With Regional Right Ventricular Systolic Dysfunction And Dyssynchrony: Strain and Strain Rate Assessment Using Velocity Vector Imaging Technique.
Meng, Hong , Villarraga, Hector R. , Lee, PuWai, Aijaz, Shah A, Kittipovanonth, Maytinee, Seward, James B., Chandrasekaran, Krishnaswamy

Mayo Clinic

Circulation | July 3, 2021 | Volume: 116 | Issue: suppl_16 | Pages: No page available

10.1161/circ.116.suppl_16.ii_331-c Get It

Background: Strain and strain rate has been shown to identify subtle contraction abnormalities of left ventricle. Objectives: We hypothesized that S and SR derived from velocity vector imaging (VVI) will allow early identification of global and regional RV systolic function in patients with pulmonary hypertension (PHT) compared to conventional echo parameters. Methods: 96 patients, 35 normal RV Systolic Pressure (RVSP < 30 mmHg) and 61 with PHT, {24 mild-moderate (RVSP > 60 mmHg) and 37 severe (RVSP < 60 mmHg)} underwent echo-Doppler assessment of RV. Apical 4 chamber images at end expiration were used for RV lateral wall (LW) and ventricular septal (VS) segment analysis for systolic tangential velocity (Ta V), S and SR. In addition RV end systolic and diastolic area, RV fractional area change (RV FAC), RV performance index (RIMP) and tricuspid annulus systolic excursion were measured. Results: Peak S, systolic SR and Ta V at the basal, mid and apical segments of the RV LW and VS were depressed in patients with PHT compared with controls, Table 1 , P 0.001. Similarly, significant decrease in RIMP was seen in patients with PHT compared to controls, p <0.001. Significant correlation (p<0.001, r >0.6) was noted between the 2D FAC and S, SR. The time to peak systolic S indexed to end diastolic area (EDA) is significantly prolonged, p<0.01 in all segments in patients with PHT indicating dyssynchrony. Conclusion: S and SR allows assesment of Regional RV systolic function otherwise difficult to assess from conventional echo-Doppler technique. PHTN is associated with not only regional RV systolic dysfunction but also with dyssynchrony. Thus, this new tool can offer new insights in the functioning of right ventricular global and regional function. mean±SD of strain
Abstract 1544: Early Statin Therapy Reduces Risk Of ICD Shocks In Patients With An Implantable Cardioverter-defibrillator Undergoing Ablation For Ventricular Tachycardia
Bunch, T. Jared , Friedman, Paul A. , Brady, Peter A. , Cha, Yong‐Mei , Hammill, Stephen C., Monahan, Kristi H. , Munger, Thomas M. , Rea, Robert F., Shen, Win K., Tabatabaei, Niloufar, Packer, Douglas L. , Gersh, Bernard J. , Asirvatham, Samuel J. , Jahangir, Arshad

Mayo Clinic

Circulation | July 3, 2021 | Volume: 116 | Issue: suppl_16 | Pages: No page available

10.1161/circ.116.suppl_16.ii_320-c Get It

Background : Lipid lowering therapy reduces mortality in patients with both ischemic and nonischemic cardiomyopathies and recently has been shown to decrease ICD shocks. Radiofrequency ablation (RFA) of recurrent VT in patients with an ICD also reduces shocks following intervention. It is unclear if statin therapy after VT RFA will further impact ICD shock rates. Methods : All patients from 1993–2005 who underwent a RFA procedure for recurrent VT at the Mayo Clinic with an ICD were included. Patient records were extracted for medical and procedural details and all ICD interrogations were reviewed for VT recurrence and therapies. Results: 63 patients (age 62±15 years) were followed over 3.9±3.6 years. Comorbid diseases included: coronary artery disease 37(58%, 34 prior myocardial infarction), ARVD/C 6(10%), nonischemic dilated cardiomyopathy 7(11%), moderate-severe valve disease 14(22%), hypertension 34(54%), and hyperlipidemia 35(56%). Ejection fraction was <0.35 in 34(56%). VT was induced in all patients (LV 55 (LVOT 1), RV 8 (RVOT 3) with multiple inducible VTs in 21(33%). VT was noninducible after RFA in 39(62%) patients. Dismissal medications included: statins 19(30%), beta blockers 40(66%), ACE/ARB 37(61%), diuretics 34(55%), and digoxin 23(37%). 5-year overall survival was 63%(95% CI 55–71). Age, diabetes, and renal insufficiency were associated with increased post ablation mortality, with no medication improving survival. 5-year survival free of ICD shocks was 31%(95% CI 24–38). Only statin therapy at discharge was associated with a decreased risk of ICD shocks [5(26%) versus 26(59%), p=0.020]. 7 additional patients received statins during follow-up, but not at discharge, of these 5(71%) had shocks. Conclusion : Statin use at discharge in patients with an ICD undergoing RFA for refractory VT significantly reduced recurrent ventricular arrhythmias and ICD shocks. Although the mechanism underlying the effects of statins on arrhythmic recurrence early after RFA requires further study, these data support aggressive therapy of the underlying substrate responsible for the VT.
Abstract 1493: Erythropoietin Stimulates Endothelial Biosynthesis of Tetrahydrobiopterin by Activation of Phosphatidylinositol 3-kinase/Protein Kinase B Signal Transduction Pathway
Santhanam, Anantha V., Katušić, Zvonimir S. , d’Uscio, Livius V. , Santhanam, Anantha Vijay R.

Mayo Clinic

Circulation | July 3, 2021 | Volume: 116 | Issue: suppl_16 | Pages: No page available

10.1161/circ.116.suppl_16.ii_308 Get It

Erythropoietin (EPO) has been recognized as a tissue protective cytokine. Recently, it has been shown that vascular protective effects of EPO are dependent on activation of endothelial nitric oxide synthase (eNOS). Tetrahydrobiopterin (BH 4 ) is an essential cofactor required for enzymatic activity of eNOS. Therefore, our objective was to characterize the effect of EPO on biosynthesis of BH 4 in vascular wall. Incubation of isolated wild-type (C57BL/6J) mouse aortas for 18 hours at 37°C in minimal essential medium supplemented with recombinant human EPO (1–50 U/ml) caused concentration-dependent increase in intracellular levels of BH 4 as determined by HPLC analysis. Maximum biosynthesis of BH 4 was detected at therapeutic concentrations of 5 U/mL (15.8±1.3 pmol/mg protein; P<0.05 vs control: 8.2±0.4 pmol/mg protein; n=6 – 8). Oxidative products of BH 4 , 7,8-dihydrobiopterin, were unaffected by EPO indicating that EPO does not affect oxidation of BH 4 . Removal of the endothelium abolished EPO-induced biosynthesis of BH 4 (P<0.05; n=5) demonstrating that the vascular endothelium is a major source of BH 4 . Treatment of intact isolated wild-type mouse aortas with a selective phosphatidylinositol (PI)3-kinase inhibitor wortmannin (1 μM) significantly reduced BH 4 biosynthesis by EPO (8.4±0.6 pmol/mg protein; P<0.05; n=6). Stimulatory effect of EPO on production of BH 4 in aorta was also detected in wild-type mice treated with recombinant human EPO (1000 U/kg, s.c. biweekly) for 14 days (P<0.05; n=6). This vascular effect was abolished in protein kinase B (Akt) 1-deficient mice treated with EPO (P<0.05; n=5). Furthermore, aortic GTP cyclohydrolase I (GTPCH I) enzymatic activity was augmented in EPO treated wild-type mice (0.48±0.12 pmol neopterin/mg protein; P<0.05 vs control: 0.23±0.05 pmol neopterin/mg; n=4) but not in EPO treated Akt 1-deficient mice (0.21±0.03 pmol neopterin/mg; n=4), indicating that the selective increase in BH 4 levels was caused by de-novo biosynthesis of BH 4 via Akt/GTPCH I pathway. Our results demonstrate that EPO stimulates biosynthesis of BH 4 in vascular endothelium. This effect is most likely designed to provide optimal intracellular concentration of cofactor necessary for EPO-induced elevation of eNOS activity.
Abstract 1382: AlbuBNP (Cardeva), a Novel Recombinant Human B-Type Natriuretic Peptide Serum Albumin Fusion Protein Has Prolonged Renal Enhancing Properties When Compared to Human BNP.
Chen, Horng H. , Matrin, Fernando L, Schirger, John A., Burnett, John C. , Cataliotti, Alessandro

Mayo Clinic

Circulation | July 3, 2021 | Volume: 116 | Issue: suppl_16 | Pages: No page available

10.1161/circ.116.suppl_16.ii_284 Get It

BACKGROUND: AlbuBNP is a novel recombinant human BNP serum albumin fusion protein which possesses a significantly longer elimination half-life compared to BNP. To date, it remains unclear if this novel protein which represents a single molecule of BNP synthesized with the carrier protein albumin can enter the post glomerular/tubular system due to the fusion of BNP to albumin and mediate renal actions. We hypothesized that this fusion protein will have potent renal actions and possess prolonged renal hemodynamic enhancing and excretory properties based upon its unique structure as compared to native BNP. METHODS: We compared the cardiorenal and humoral actions of intravenous(IV) bolus of administration of AlbuBNP (Cardeva, CoGenesys, Rockville MD) (5 mg/kg, n=7) and Human BNP (Phoenix Pharmaceutical, Belmont CA) (25 μ g/Kg, n=5) in two groups of normal anesthetized dogs. * p<0.05 RESULTS: Single IV bolus of AlbuBNP resulted in a sustained increase in plasma cGMP (5±1 to 9±2 pmol/ml*) and urinary cGMP excretion (1136±113 to 2556±417 pmol/min*), markers of the biological activity of BNP, which remained elevated at the termination of the experiment at 270 minutes. In contrast, with human BNP, both plasma and urinary cGMP peaked at 30 minutes and returned to baseline by 150 minutes. In a similar fashion, there was a sustained increase in natriuresis (39±12 to 159±38 μEq/min*), diuresis (0.2±0.1 to 1.1±0.3 ml/min*), renal blood flow (220±22 to 301±33 ml/min*), and glomerular filtration rate (34±2 to 62±13 ml/min*) with AlbuBNP while with human BNP, these renal effects peaked at 30 minutes and returned to baseline by 150 minutes. Furthermore, there was a gradual and sustained suppression of plasma aldosterone (7.8±2 to 3.6±1 ng/dL*) with AlbuBNP. Likewise, there was a more sustained reduction of cardiac filling pressures with AlbuBNP as compared to human BNP. CONCLUSION: We report for the first time that this newly developed BNP/albumin fusion protein has a more prolonged and sustained renal enhancing properties compared to human BNP. Thus, AlbuBNP (Cardeva) represents a novel long-acting renal enhancing and aldosterone suppressing drug which has therapeutic potential for the management of cardiovascular and renal diseases that should be defined in further studies.